Table 2.
Associations between risk score and characteristics of patients with ovarian cancer in the training cohort.
| Characteristic |
Low-risk group (n = 125) |
High-risk group (n = 125) |
P-Value |
|---|---|---|---|
| Age, mean ± SD | 57.84 ± 11.35 | 59.68 ± 11.52 | 0.205 |
| Race, n (%) | 0.188 | ||
| Asian | 4 (3.3%) | 4 (3.3%) | |
| Black or African American | 4 (3.3%) | 12 (9.8%) | |
| Other | 1 (0.8%) | 1 (0.8%) | |
| White | 112 (92.6%) | 105 (86.1%) | |
| Anatomic subdivision, n (%) | 0.812 | ||
| Unilateral | 31 (25.8%) | 32 (28.1%) | |
| Bilateral | 89 (74.2%) | 82 (71.9%) | |
| Lymphatic invasion, n (%) | 1.000 | ||
| No | 19 (34.5%) | 15 (33.3%) | |
| Yes | 36 (65.5%) | 30 (66.7%) | |
| Neoplasm histologic grade, n (%) | 0.815 | ||
| G2 | 19 (15.3%) | 16 (13.4%) | |
| G3 | 105 (84.7%) | 103 (86.6%) | |
| Clinical stage, n (%) | 0.114 | ||
| Stage I | 0 (0%) | 1 (0.8%) | |
| Stage II | 12 (9.6%) | 4 (3.3%) | |
| Stage III | 97 (77.6%) | 98 (79.7%) | |
| Stage IV | 16 (12.8%) | 20 (16.3%) | |
| Chemotherapy, n (%) | 0.056 | ||
| No | 5 (4%) | 14 (11.2%) | |
| Yes | 120 (96%) | 111 (88.8%) | |
| Hormone therapy, n (%) | 0.816 | ||
| No | 116 (92.8%) | 114 (91.2%) | |
| Yes | 9 (7.2%) | 11 (8.8%) | |
| Targeted molecular therapy, n (%) | 0.189 | ||
| No | 110 (88%) | 117 (93.6%) | |
| Yes | 15 (12%) | 8 (6.4%) | |
| Immunotherapy, n (%) | 0.500 | ||
| No | 119 (95.2%) | 122 (97.6%) | |
| Yes | 6 (4.8%) | 3 (2.4%) | |